MX9701820A - Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf. - Google Patents

Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.

Info

Publication number
MX9701820A
MX9701820A MX9701820A MX9701820A MX9701820A MX 9701820 A MX9701820 A MX 9701820A MX 9701820 A MX9701820 A MX 9701820A MX 9701820 A MX9701820 A MX 9701820A MX 9701820 A MX9701820 A MX 9701820A
Authority
MX
Mexico
Prior art keywords
pyrazolo
tyrosine kinase
protein tyrosine
pdgf receptor
quinoxaline compounds
Prior art date
Application number
MX9701820A
Other languages
English (en)
Other versions
MXPA97001820A (es
Inventor
Michael R Myers
Paul E Persons
Cuong Q Ly
Alfred P Spada
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of MXPA97001820A publication Critical patent/MXPA97001820A/es
Publication of MX9701820A publication Critical patent/MX9701820A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion se refiere a compuestos pirazolo[3,4-g]quinoxalina que exhiben actividad de inhibicion de la proteína tirosina cinasa. Más específicamente, los compuestos de esta invencion son novedosos como inhibidores selectivos de la proteína tirosina cinasa PDGF-R y se pueden aplicar como agentes terapéuticos potenciales para varios estados morbidos que se caracterizan por la proliferacion celular no controlada. Además, la presente invencion provee composiciones farmacéuticas y un método para tratar tales desordenes que consta de la administracion, a un paciente de una cantidad eficaz para inhibir el receptor PDGF de un compuesto de pirazolo[3,4-g]quinoxalina que exhibe actividad de inhibicion de la proteína tirosina cinasa. Procedimientos para la preparacion de los compuestos de pirazolo[3,4-g]quinoxalina.
MX9701820A 1994-09-08 1995-09-06 Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf. MX9701820A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08303097 1994-09-08
US08/303,097 US5476851A (en) 1994-09-08 1994-09-08 Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
PCT/US1995/011414 WO1996007658A1 (en) 1994-09-08 1995-09-06 PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE

Publications (2)

Publication Number Publication Date
MXPA97001820A MXPA97001820A (es) 1997-06-01
MX9701820A true MX9701820A (es) 1997-06-28

Family

ID=23170524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701820A MX9701820A (es) 1994-09-08 1995-09-06 Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.

Country Status (10)

Country Link
US (1) US5476851A (es)
EP (1) EP0779889B1 (es)
JP (1) JP3952313B2 (es)
AT (1) ATE269865T1 (es)
AU (1) AU697518B2 (es)
CA (1) CA2198005C (es)
DE (1) DE69533194T2 (es)
ES (1) ES2224134T3 (es)
MX (1) MX9701820A (es)
WO (1) WO1996007658A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329375B1 (en) 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
WO2002083075A2 (en) * 2001-04-16 2002-10-24 Uab Research Foundation Akt and regulation of ra synovial fibroblast apoptosis
DE60326950D1 (de) * 2002-05-15 2009-05-14 Janssen Pharmaceutica Nv N-substituierte tricyclische 3-aminopyrazole als pdgf rezeptorenhemmer
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP3168304A1 (en) 2003-08-27 2017-05-17 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1682516A2 (en) * 2003-11-13 2006-07-26 Janssen Pharmaceutica N.V. Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
WO2006040522A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinoline derivatives
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN112020357B (zh) * 2019-04-02 2023-08-29 上海翰森生物医药科技有限公司 含吲唑基的三并环类衍生物的盐及其晶型
WO2021191219A1 (en) * 2020-03-23 2021-09-30 Helmholtz-Zentrum für Infektionsforschung GmbH N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3701277A1 (de) * 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
DK160941C (da) * 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2198005C (en) 2007-06-12
DE69533194D1 (de) 2004-07-29
JPH10505093A (ja) 1998-05-19
EP0779889A4 (en) 2000-02-23
JP3952313B2 (ja) 2007-08-01
CA2198005A1 (en) 1996-03-14
AU697518B2 (en) 1998-10-08
DE69533194T2 (de) 2005-08-11
WO1996007658A1 (en) 1996-03-14
ATE269865T1 (de) 2004-07-15
EP0779889A1 (en) 1997-06-25
EP0779889B1 (en) 2004-06-23
ES2224134T3 (es) 2005-03-01
US5476851A (en) 1995-12-19
AU3549195A (en) 1996-03-27

Similar Documents

Publication Publication Date Title
MX9701820A (es) Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
MY117696A (en) INHIBITORS OF p38
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
GR3022459T3 (en) Quinuclidine derivative as substance p antagonist.
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
CA2252515A1 (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
IL192287A0 (en) Pharmaceutical compositions and methods for use
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
ATE202709T1 (de) Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
PL350891A1 (en) Substituted 1,4-dichlorindene[1,2-c]pyrazoles as inhibitors of tyrosine kinase
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
BG103512A (en) Substituted pyramidine compounds and their application
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
WO2000004012A8 (en) COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
ATE229953T1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE60121978D1 (de) 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN